Novel oral chemotherapeutic holds potential for stomach cancer patients - European Pharmaceutical Review

Carl Bjartmar of Ascelia Pharma explores the benefits of oral therapeutic administration over intravenous chemotherapy for stomach cancer patients, highlighting improvements in efficacy and ease of use.

Posted: 5 July 2022 | Carl Bjartmar (Ascelia Pharma) | No comments yet Carl Bjartmar, Chief Medical Officer at Ascelia Pharma, explores the benefits of oral therapeutic administration over intraveno… [+12006 chars]

full article...